Umoja Biopharma
Facts
- HQ
- Seattle, USA
- Sectors
- Biotechnology Research
- Founded
- 2019
- Type
- Corporation Seattle business license
- Employees
- 254
- Registered name
- Umoja Biopharma Inc Seattle business license
- Total raised
- $210M SEC Form D filings Total of this company's SEC Form D filings
- Last round
- $210M · Jun 2021 SEC Form D
BrainChild Bio raises $116M Series A to fund Phase 2 CAR‑T trial for pediatric diffuse intrinsic pontine glioma
BrainChild Bio raised $116 million in Series A financing to advance CAR-T therapies into the central nervous system, funding a Phase 2 trial of its lead candidate for pediatric diffuse intrinsic pontine glioma while planning future adult indications.
Seattle Immunotherapy Startup Umoja Biopharma Raises $100M Series C to Advance In Vivo CAR T-Cell Cancer Therapies
Seattle-based Umoja Biopharma raised $100 million in a Series C funding round to advance its CAR T-cell immunotherapy treatments, including an in vivo cell-generating technology for cancer. The company, founded in 2019 and led by CEO Andy Scharenberg, has programs in preclinical and Phase 1 stages and previously raised $263 million.
Seattle Children’s Launches BrainChild Bio Startup to Develop CAR T-Cell Therapies for Pediatric Brain Cancer
Seattle Children’s has spun out BrainChild Bio, a biotech startup focused on developing CAR T-cell therapies for incurable pediatric brain cancers like diffuse intrinsic pontine glioma. Led by Dr. Michael Jensen, the company will operate from the Building Cure innovation hub in downtown Seattle.
Seagen CEO Clay Siegall Resigns Effective May 15 Following April 2022 Domestic Violence Arrest
Clay Siegall resigned as CEO and chairman of Seagen following his arrest on domestic violence charges, effective May 15, 2022. Seagen’s board accepted his resignation and named interim CEO Roger Dansey while accelerating Siegall’s equity awards and providing severance.
Seagen CEO Clay Siegall Takes Leave Amid Domestic Violence Allegations; Shares Fall 8%
Seagen CEO Clay Siegall is on leave amid allegations of domestic violence, which he denies, as the company investigates with interim CEO Roger Dansey appointed. Shares dropped over 8% following the news, while Seagen emphasizes its high standards for employee conduct.
U.S. VC Hits $330B in 2021; Washington State Pulls $8.5B Across 549 Deals, 9 New Seattle Unicorns
Venture capital hit record highs in the U.S. in 2021 with $330 billion across 17,054 deals, and Washington state saw $8.5 billion invested in 549 deals (a 77% increase over 2020), driven in part by newly minted unicorns in the Seattle area.
Affini-T Therapeutics launched by Fred Hutch scientists including Juno co-founder Philip Greenberg to develop engineered TCR cancer therapies
Affini-T Therapeutics, founded by Fred Hutch scientists including Philip Greenberg (a Juno co-founder), Aude Chapuis and Thomas Schmitt, launched to develop T cell receptor (TCR) cancer immunotherapies that add engineered CD8 co-receptors and other gene edits. The Boston-headquartered company, led by CEO Jak Knowles, was unveiled at the J.P. Morgan Health Care Conference and will operate a research lab in Seattle.
CBRE: U.S. life-sciences VC tops $30B; Seattle-area firms raise $898M amid scarce lab space
A CBRE report shows U.S. life sciences venture funding topped $30 billion for the 12 months ending September 2021, driving strong demand for lab space and record capital raises in Seattle-area companies that pulled in $898 million during that period. Washington state also saw rising life-science employment and multiple biotech IPOs in 2021, including large offerings from Sana Biotechnology, Absci and Icosavax.
Alexandria Executive Chairman Joel Marcus Says Pandemic Is Shifting Biotech Toward Hubs Like Seattle as Investment Surges
Alexandria Real Estate Equities chairman Joel Marcus says the pandemic is accelerating biotech investment and changing industry geography, reinforcing hubs like Seattle where his company has extensive lab real estate, tenants, and venture investments.
Umoja Biopharma raises $210M Series B to advance in‑vivo T‑cell immunotherapies after $53M Series A seven months earlier
Umoja Biopharma, a Seattle-based immunotherapy startup, raised $210 million in a Series B just seven months after a $53 million Series A to advance in‑vivo T‑cell cancer therapies and tumor‑tagging technology into clinical trials for solid and hematological tumors.
Notch Therapeutics raises $85M Series A (total $91M) to fund stem cell–derived T cell therapies and open Seattle lab
Notch Therapeutics raised an $85 million Series A, bringing total funding to $91 million, to advance stem cell–derived T cell immunotherapies and expand with a new Seattle research lab. The 2018-founded biotech plans to grow from 35 to about 100 employees by end of 2022 and is collaborating with Allogene Therapeutics on treatments for blood cancers.
U.S. Startups Raised Record $156.2B in 2020; Pacific Northwest Logged $946M in Q4 Across 54 Deals
U.S. startups set a new annual VC funding record in 2020 with $156.2 billion raised, driven by digital acceleration during the pandemic and a surge in mega-deals; Q4 saw $946 million invested across 54 Pacific Northwest deals. VC fundraises also hit records and IPO activity boosted exit values, suggesting continued momentum into 2021 as investors hold dry powder.
Umoja Biopharma raises $53M Series A to develop in vivo CAR T-cell immunotherapies for adult and pediatric tumors
Seattle-based Umoja Biopharma raised $53 million in a Series A to advance its preclinical in vivo CAR T-cell immunotherapy platform for blood and organ tumors in adult and pediatric patients, aiming to generate cancer-fighting cells inside the body. The company was founded last year by CEO Andy Scharenberg and collaborators from Seattle Children’s Research Institute and Purdue University, with MPM Capital and Qiming Venture Partners USA leading the round.
People
-
Andy Scharenberg Executive Officer, Director
